Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 143 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR Seven Extra Years July 2, 2022 Droplet Transmission vs. Airborne… What’s the difference? August 10, 2020 Investment Needed to Bring Down Pancreatic Cancer Death Rates in Europe.... February 22, 2021 FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer August 2, 2021 Load more HOT NEWS A radical project: video game design meets cancer research A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year... Understanding Serving Sizes Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention...
